GlassScriptPhysician profile
Philip John Brondon
NPI 1770877037
$5,925.22
in general payments reported to CMS, 2019-2025
38 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $265 · 2021: $160 · 2022: $537 · 2023: $1,439 · 2024: $1,291 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,945.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,564.20 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $589.18 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $413.87 | 2019-2025 | Epclusa |
| Pfizer INC. | $380.65 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $287.53 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $284.74 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.00 | 2019-2025 | Xifaxan, Plenvu, Uceris |
| Braintree Laboratories, INC. | $227.86 | 2019-2023 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $210.61 | 2022-2025 | Dupixent |
| Celgene Corporation | $192.37 | 2022-2024 | Zeposia |
| Daiichi Sankyo INC. | $163.43 | 2019-2024 | Injectafer |
| Lilly USA, LLC | $127.35 | 2024-2025 | Omvoh, Zepbound |
| Merck Sharp & Dohme LLC | $105.12 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $103.50 | 2023-2025 | Ocaliva |
| Organon LLC | $98.66 | 2023-2024 | Hadlima, Renflexis |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Brondon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.